Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP101 + Gemcitabine in Advanced Pancreatic Cancer
NCT00550004Phase 2Terminated
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Sep 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of brivudine in pancreatic adenocarcinoma (PDAC), sponsored by SciClone Pharmaceuticals (Holdings) Limited. Started Sep 2007; status: terminated.
02
Drugs
brivudine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00550004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550004.